Alkermes plc (ALKS) Completes Enrollment in Key Narcolepsy Trial, Data Due Q3 2025

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Alkermes plc is one of them.

Alkermes plc (NASDAQ:ALKS) tops our list for being one of the best psychedelic stocks. It is an Ireland-based biopharmaceutical company with U.S. operations, and specializes in treatments for complex psychiatric and neurological conditions, including alcohol and opioid dependence, schizophrenia, and bipolar I disorder. The company leverages its neuroscience expertise to develop innovative therapies, with an active pipeline targeting disorders such as narcolepsy and idiopathic hypersomnia.

A major focus is alixorexton (formerly ALKS 2680), a novel oral orexin 2 receptor agonist currently in Phase 2 trials for narcolepsy types 1 and 2, as well as idiopathic hypersomnia. Enrollment in the Vibrance-1 Phase 2 study for narcolepsy type 1 has been completed, with topline data expected in early Q3 2025. Early Phase 1/1b results indicate the drug is well-tolerated, improves wakefulness, and shows no cardiac safety concerns. Detailed findings will be presented at the World Sleep Congress 2025, highlighting patient-reported outcomes and efficacy. This development underscores Alkermes plc (NASDAQ:ALKS)’ commitment to addressing unmet needs in sleep disorders.

Alongside pipeline progress, Alkermes plc (NASDAQ:ALKS) continues strong commercial performance with products like VIVITROL, ARISTADA, and LYBALVI, the latter showing notable year-over-year revenue growth. The company reinvests profits into research and development rather than dividends, maintaining a robust cash position to support innovation. Recent survey findings on alcohol use disorder further illustrate the corporation’s patient-centric approach, emphasizing its strategic focus on combining commercial success with cutting-edge neuroscience therapies

While we acknowledge the potential of ALKS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.